LP-102

LP-102 is a code name that refers to multiple distinct investigational drugs developed by different companies for different indications. 1. **LB Pharmaceuticals' LP-102 (also known as LB-102):** An N-methylated analogue of amisulpride, this is a once-daily, orally administered small molecule and potential first-in-class benzamide antipsychotic in the United States. It acts as a dopamine D2/3 receptor antagonist. Positive topline results from a Phase 2 trial (NOVA 1) in acute schizophrenia were announced in January 2025, showing statistically significant improvement in PANSS total score and a favorable safety profile. 2. **LPOXY Therapeutics' LP-102:** An oxygen therapy administered orally as a capsule, based on enteric aerobization, for inflammatory bowel diseases including ulcerative colitis and Crohn's disease. It was also previously under development for neuromyelitis optica. 3. **Guangzhou LintonPharm's LP-102:** A bispecific T-cell engager (BiTE) that acts as a CD3 stimulant, in preclinical development for chronic lymphocytic leukemia.